Drug Trial Radar · NCT06130553
A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
334
Planned (sponsor's estimate)
Start
Jan 18, 2024
Primary completion
Dec 4, 2028
Study completion Dec 4, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several study modules, evaluating the safety, tolerability, pharmacokinetic (PK), pharmacodynamics, and preliminary efficacy of AZD3470 as monotherapy or in combination with other anti-cancer agents.
Conditions
- Advanced Solid Tumors That Are MTAP Deficient
Interventions
AZD3470Drug
AZD3470 is a novel, potent and selective, second-generation, MTAP-selective, inhibitor of PRMT5.
Datopotamab deruxtecanDrug
AZD3470 in combination with Dato-DXd + Dato-Dxd monotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- All Modules: Incidence of adverse events (AEs) and serious adverse events (SAEs). To determine the RP2D of AZD3470 as monotherapy and in combination with anticancer agentsTime frame: From time of informed consent to 28 days post last dose of study treatment
- Module 1: Incidence of dose-limiting toxicities (DLT)Time frame: From first dose of study treatment until the end of Cycle 1 (each cycle is 21 days)
- Module 2: Progression Free Survival assessed by the Investigator according to RECIST v1.1Time frame: From date of randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years).
Locations
21 sites in 8 countries. Site status is shown where the registry gives one.
Research Site
San Francisco, California · Recruiting
Research Site
West Hollywood, California · Withdrawn
Research Site
New Haven, Connecticut · Recruiting
Research Site
Baltimore, Maryland · Recruiting
Research Site
Portland, Oregon · Recruiting
Research Site
Pittsburgh, Pennsylvania · Recruiting
Research Site
Providence, Rhode Island · Recruiting
Research Site
Fairfax, Virginia · Recruiting
Research Site
Melbourne, Australia · Recruiting
Research Site
Beijing, China · Recruiting
Research Site
Chengdu, China · Recruiting
Research Site
Shanghai, China · Recruiting
Research Site
Wuhan, China · Not yet recruiting
Research Site
Villejuif, France · Not yet recruiting
Research Site
Chūōku, Japan · Recruiting
Research Site
Kashiwa, Japan · Recruiting
Research Site
Amsterdam, Netherlands · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Barcelona, Spain · Recruiting
Research Site
Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.